These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9562213

  • 21. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
    Shimoda K, Morita S, Hirokane G, Yokono A, Someya T, Takahashi S.
    Pharmacol Toxicol; 2000 Jun; 86(6):245-9. PubMed ID: 10895986
    [Abstract] [Full Text] [Related]

  • 22. [Chronic discomfort with dentures - successful treatment with clomipramine].
    Hain C.
    Psychiatr Prax; 2001 Sep; 28(6):303-4. PubMed ID: 11678084
    [No Abstract] [Full Text] [Related]

  • 23. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T.
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [Abstract] [Full Text] [Related]

  • 24. A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration.
    Terao T, Ohmori O, Shinkai T.
    Acta Psychiatr Scand; 1999 May; 99(5):388-90; discussion 390-2. PubMed ID: 10353456
    [Abstract] [Full Text] [Related]

  • 25. Severe adverse drug events under combination of nortriptyline and melperone due to pharmacokinetic interaction.
    Hefner G, Geschke K, Hiemke C.
    J Clin Psychopharmacol; 2014 Jun; 34(3):394-6. PubMed ID: 24743723
    [No Abstract] [Full Text] [Related]

  • 26. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [Abstract] [Full Text] [Related]

  • 27. [Cytochrome p450 IID6, its role in psychopharmacology].
    Lamard L, Pérault MC, Bouquet S, Guibert S.
    Ann Med Psychol (Paris); 1995 Feb; 153(2):140-3. PubMed ID: 7741408
    [Abstract] [Full Text] [Related]

  • 28. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
    Paulzen M, Tauber SC, Kirner-Veselinovic A, Gründer G.
    J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
    [No Abstract] [Full Text] [Related]

  • 29. A double-blind, comparative study of dothiepin and clomipramine in the treatment of major depressive illness.
    Welch CP, Tweed JA, Smithers A, Gostick NK, Raniwalla J.
    Int J Clin Pract; 1997 Sep; 51(6):360-3. PubMed ID: 9489063
    [Abstract] [Full Text] [Related]

  • 30. [Interaction between paroxetine and clomipramine as a possible reason for admission to a department of internal medicine].
    Skjelbo EF, Brøsen K.
    Ugeskr Laeger; 1998 Sep 21; 160(39):5665-6. PubMed ID: 9771062
    [Abstract] [Full Text] [Related]

  • 31. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
    Lee SY, Ki CS, Hong KS, Kim JW.
    J Korean Med Sci; 2004 Oct 21; 19(5):750-2. PubMed ID: 15483356
    [Abstract] [Full Text] [Related]

  • 32. Diabetes mellitus associated with clomipramine treatment: a retrospective analysis.
    Mumoli N, Cocciolo M, Vitale J, Mantellassi M, Sabatini S, Gambaccini L, Cei M.
    Acta Diabetol; 2014 Feb 21; 51(1):167-8. PubMed ID: 23824324
    [Abstract] [Full Text] [Related]

  • 33. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
    Pérez de los Cobos J, Siñol N, Trujols J, del Río E, Bañuls E, Luquero E, Menoyo A, Queraltó JM, Baiget M, Alvarez E.
    Drug Alcohol Depend; 2007 Jul 10; 89(2-3):190-4. PubMed ID: 17234366
    [Abstract] [Full Text] [Related]

  • 34. [Clinical pharmacokinetics of tricyclic antidepressants. Part I. Pharmacokinetic properties].
    Szymura-Oleksiak J, Wasieczko A, Wyska E, Zieba A.
    Psychiatr Pol; 1993 Jul 10; 27(6):683-91. PubMed ID: 8134502
    [Abstract] [Full Text] [Related]

  • 35. [Results of using tricyclic antidepressive drugs in the treatment of endogenous depression (comparative analysis of 7 drugs)].
    Beresewicz M, Bidzińska E, Koszewska I, Puzyński S.
    Psychiatr Pol; 1991 Jul 10; 25(3-4):13-8. PubMed ID: 1687987
    [Abstract] [Full Text] [Related]

  • 36. CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?
    Macaluso M, Preskorn SH.
    J Clin Psychopharmacol; 2011 Apr 10; 31(2):143-5. PubMed ID: 21346604
    [No Abstract] [Full Text] [Related]

  • 37. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M, Grzesiak M, Beszłej JA, Kiejna A.
    Psychiatr Pol; 2004 Apr 10; 38(6):1093-104. PubMed ID: 15779673
    [Abstract] [Full Text] [Related]

  • 38. [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
    Stephan PL, Etzensberger M, Jaquenoud Sirot E.
    Praxis (Bern 1994); 2006 Apr 26; 95(17):671-8. PubMed ID: 16686323
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice.
    Pfuhlmann B, Gerlach M, Burger R, Gonska S, Unterecker S, Jabs B, Riederer P, Deckert J.
    J Neural Transm Suppl; 2007 Apr 26; (72):287-96. PubMed ID: 17982905
    [Abstract] [Full Text] [Related]

  • 40. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
    Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl ML, Ingelman-Sundberg M, Bertilsson L.
    Pharmacogenetics; 1999 Oct 26; 9(5):657-60. PubMed ID: 10591547
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.